Cargando…

Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis

BACKGROUND: Although direct-acting antivirals (DAA) have revolutionized the treatment of chronic hepatitis C virus (HCV), many state Medicaid programs have limited coverage because of their expense. In 2015, the Centers for Medicare & Medicaid Services (CMS) notified states about the legality of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herink, Megan C, Geddes, Jonah, Vo, Kim, Zaman, Atif, Hartung, Daniel M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391280/ https://www.ncbi.nlm.nih.gov/pubmed/34185560 http://dx.doi.org/10.18553/jmcp.2021.27.7.856

Ejemplares similares

Measuring the impact of the Affordable Care Act Medicaid expansion on access to primary care using an interrupted time series approach
por: Brown, Elizabeth A., et al.
Publicado: (2021)

Direct‐Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C
por: Park, Haesuk, et al.
Publicado: (2020)

Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid
por: Pham, Timothy T., et al.
Publicado: (2018)

Correction to: Measuring the impact of the Afordable Care Act Medicaid expansion on access to primary care using an interrupted time series approach
por: Brown, Elizabeth A., et al.
Publicado: (2021)

Evaluation of a Medicaid performance improvement project to reduce high-dose opioid prescriptions
por: Hartung, Daniel M., et al.
Publicado: (2022)

Medicaid expansion and treatment for opioid use disorders in Oregon: an interrupted time-series analysis
por: McCarty, Dennis, et al.
Publicado: (2019)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Dispensing of HIV and Hepatitis C Antivirals During COVID-19: An Interrupted Time-Series Analysis of U.S. National Data
por: Levengood, Timothy W., et al.
Publicado: (2022)

Crushing and Splitting Direct-Acting Antivirals for Hepatitis C Virus Treatment: A Case Series and Literature Review
por: Whelchel, Kristen, et al.
Publicado: (2021)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study
por: Hartung, Daniel M., et al.
Publicado: (2022)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19
por: Kumar, Pramod, et al.
Publicado: (2021)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
por: John, Jason J., et al.
Publicado: (2021)

Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis
por: Zhang, Hang, et al.
Publicado: (2023)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
por: Wang, Yadong, et al.
Publicado: (2022)

Effect of reimbursement restriction policy on the use of benzodiazepines in the Netherlands: an interrupted time series analysis
por: Stoker, Lennart Jan, et al.
Publicado: (2019)

Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection
por: Salama, Iman Ibrahim, et al.
Publicado: (2022)

The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis
por: Meeker, Amanda S, et al.
Publicado: (2015)

Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
por: Gaglio, Paul J., et al.
Publicado: (2011)

Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

Managing HIV/hepatitis C co-infection in the era of direct acting antivirals
por: Rockstroh, Jürgen K, et al.
Publicado: (2013)

Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods
por: Loggi, Elisabetta, et al.
Publicado: (2017)

Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India
por: Gupta, Varun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vjbpmjjsnlo79l1b56svbq8m09